The B-Raf is the essential protein in signal pathways inside cells which is affected by cell growth direction. The B-Raf protein encoded by the BRAF gene that is located at chromosome 7, BRAF gene is also pointed out as proto-oncogene. This study aimed to detect the substitution at codon 600 causing a change of valine to glutamic acid (V600E) mutation in Iraqi females to assist its role in initiating breast cancer. Sixty biopsies tissue from breast cancer Iraqi women and 20 women with benign lesions were enrolled in this study. DNA was extracted from breast cancer biopsies samples. PCR and DNA Sequencing techniques were used to screen the BRAF V600E gene mutation as it is an essential event in the initiation of cancer. The results revealed that none Iraqi breast cancer women had BRAF V600E mutation, The annotated BRAF gene has been deposited in DDBJ/GenBank under the accession number LC547435. In conclusion: The present data indicate no BRAF V600E mutation in Iraqi breast cancer females and may not possess a role in breast cancer initiation. The current results may be refer to ineffectiveness of Vemurafenib and Encorafenib therapies that specific for patients with the BRAF V600 mutation. Other studies with large numbers of patients are needed to confirm the result of this study, as the high prevalence of breast cancer among Iraqi women.
| Published in | Advances in Bioscience and Bioengineering (Volume 12, Issue 2) |
| DOI | 10.11648/j.abb.20241202.13 |
| Page(s) | 45-49 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
BRAF V600E, Breast, Cancer, BRAF Gene, Iraq
| [1] | Heer, E., Harper, A., Escandor, N., Sung, H., McCormack, V., & Fidler-Benaoudia, M. M. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. The Lancet. Global health. (2020). 8(8), e1027–e1037. |
| [2] | Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012. 490. 61-70. |
| [3] | Ali, C. A.; Lafta, F. M; Al Sayyid, M. M. and Ghaloub Al-Rekab, A. N. BRCA1 Gene Expression is Down Regulated in Both Familial and Sporadic Breast Cancer Cases in Baghdad- Iraq. Ali et al. Iraqi Journalof Science. 2020 60(1), 34-41. |
| [4] | Hussein, S. M. Abdul Jabbar, F. A. And Khalaf, H. M. Detection of Genetic Polymorphism of HER2 Gene in HER2 Positive Breast Cancer Women in Iraq. Iraqi Journal of Science. 2021. 62(10), 3507-3520. |
| [5] | Cantwell-Dorris, E. R., O'Leary, J. J., and Sheils, O. M. BRAFV600E: implications for carcinogenesis and molecular therapy. Molecular cancer therapeutics. 2011. 10(3), 385–394. |
| [6] | Kondoh, K.; Nishida, E. Regulation of MAP Kinases by MAP Kinase Phosphatases. Biochim. Biophys. Acta. 2007, 1773, 1227–1237. [CrossRef] [PubMed]. |
| [7] | Whitmarsh, A. J. Regulation of Gene Transcription by Mitogen-Activated Protein Kinase Signaling Pathways. Biochim. Biophys. Acta, 2007.1773.1285–1298. |
| [8] | Hall, R. D., & Kudchadkar, R. R. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer control. journal of the Moffitt Cancer Center. 2014, 21(3), 221–230. |
| [9] | Cen, S., Liu, K., Zheng, Y., Shan, J., Jing, C., Gao, J., Pan, H., Bai, Z., & Liu, Z. BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. Frontiers in cell and developmental biology. 2021. l(9), 705060, |
| [10] | Yalikong, A., Li, X. Q., Zhou, P. H., Qi, Z. P., Li, B., Cai, S. L., & Zhong, Y. S. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. International journal of nanomedicine. 2021, 6, 2323–2335, |
| [11] | Kim, B., Park, S. J., Cheon, J. H.; Kim, T. I., Kim, W. H. and Hong, S. P. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. World J. Gastroenterol. 2014, 20, 4370-4376. |
| [12] | Garnett, M. J., and Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer cell. 2004, 6(4), 313–319. |
| [13] | Al-Askeri M. A. and Mutter, A. A. Mutation of BRAF V600E in Iraqi Female Patients Diagnosed With Breast Cancer. Journal of Babylon University/Pure and Applied Sciences, (26) 3, 78-830. 2018. |
| [14] | Al Musawi, I. H. N., Mahood, W. S., Jawad, M. M. Jawad, A. A. Detection of BRAF Gene in Some Iraqi Bowel Inflammation and Colorectal Cancer Patients. Ibn Al-Haitham J. for Pure & Appl. 2017, (30)1, 1-10. |
| [15] | Santarpia, L., Qi, Y., Stemke-Hale, K., Wang, B., Young, E. J., Booser, D. J., Holmes, F. A., O'Shaughnessy, J., Hellerstedt, B., Pippen, J., Vidaurre, T., Gomez, H., Valero, V., Hortobagyi, G. N., Symmans, W. F., Bottai, G., Di Leo, A., Gonzalez-Angulo, A. M., & Pusztai, L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast cancer research and treatment. 2012, 134(1), 333–343, |
| [16] | Tilch, E., Seidens, T., Cocciardi, S., Reid, L. E., Byrne, D., Simpson, P. T., Vargas, A. C., Cummings, M. C., Fox, S. B., Lakhani, S. R., & Chenevix Trench, G. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast cancer research and treatment. 2014, (143)2, 385–392, |
| [17] | Zhu, X., Li, Y., Xu, G., & Fu, C. Growth hormone receptor promotes breast cancer progression via the BRAF/MEK/ERK signaling pathway. FEBS open bio. 2020, 10(6), 1013–1020. |
| [18] | Premalatha, B. R., Patil, S., Rao, R. S., Reddy, N. P., & Indu, M. Odontogenic tumor markers - an overview. Journal of international oral health. 2013, 5(2), 59–69. |
| [19] | Jung, Y. Y.; Jung, W. H. and Koo, J. S. BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. Journal International Journal of Clinical and Experimental Pathology. 2016, 9(2), 1545-1556. |
| [20] | Wang, Y. L., Dai, X., Li, Y. D., Cheng, R. X., Deng, B., Geng, X. X., & Zhang, H. J. Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai. Genetics and molecular research. 2015, 14(4), 14840–14846.. |
| [21] | Kim. W., Jung, H. K,, Kim, Y. M., 1, Ki, W. W., Lee, J. S., Suk, J. K. (2016). BRAF Mutation from Tissue Samples in Korean Patients with Breast Cancer and Thyroid Cancer: A Pilot Study. J Korean Soc Breast Screening 2015, 12: 28-34. |
| [22] | Jeong, D., Jeong, Y., Park, J. H., Han, S. W., Kim, S. Y., Kim, Y. J., et al. BRAFV600E Mutation Analysis in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-time PCR. Annals of Surgical. 2013(20). 3, 759-66. |
| [23] | Lee, J. Y., Shin, J. H., Han, B. K., Ko, E. Y., Kang, S. S., Kim, J. Y., Oh, Y. L., & Chung, J. H. Diffuse sclerosing variant of papillary carcinoma of the thyroid: imaging and cytologic findings. Thyroid. 2007, 17(7), 567–573. |
APA Style
Mahood, W. S., Hassoon, A. H., Obaidy, S. S. A., Ahmed, L. Q., Musawi, I. H. A. (2024). Investigation of BRAF V600E Mutation in Breast Cancer Patients. Advances in Bioscience and Bioengineering, 12(2), 45-49. https://doi.org/10.11648/j.abb.20241202.13
ACS Style
Mahood, W. S.; Hassoon, A. H.; Obaidy, S. S. A.; Ahmed, L. Q.; Musawi, I. H. A. Investigation of BRAF V600E Mutation in Breast Cancer Patients. Adv. BioSci. Bioeng. 2024, 12(2), 45-49. doi: 10.11648/j.abb.20241202.13
AMA Style
Mahood WS, Hassoon AH, Obaidy SSA, Ahmed LQ, Musawi IHA. Investigation of BRAF V600E Mutation in Breast Cancer Patients. Adv BioSci Bioeng. 2024;12(2):45-49. doi: 10.11648/j.abb.20241202.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.abb.20241202.13,
author = {Wafaa Sabri Mahood and Athraa Hammed Hassoon and Shaimaa Sabah Al Obaidy and Lenha Qutaiba Ahmed and Ibtisam Hammood AL Musawi},
title = {Investigation of BRAF V600E Mutation in Breast Cancer Patients
},
journal = {Advances in Bioscience and Bioengineering},
volume = {12},
number = {2},
pages = {45-49},
doi = {10.11648/j.abb.20241202.13},
url = {https://doi.org/10.11648/j.abb.20241202.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.abb.20241202.13},
abstract = {The B-Raf is the essential protein in signal pathways inside cells which is affected by cell growth direction. The B-Raf protein encoded by the BRAF gene that is located at chromosome 7, BRAF gene is also pointed out as proto-oncogene. This study aimed to detect the substitution at codon 600 causing a change of valine to glutamic acid (V600E) mutation in Iraqi females to assist its role in initiating breast cancer. Sixty biopsies tissue from breast cancer Iraqi women and 20 women with benign lesions were enrolled in this study. DNA was extracted from breast cancer biopsies samples. PCR and DNA Sequencing techniques were used to screen the BRAF V600E gene mutation as it is an essential event in the initiation of cancer. The results revealed that none Iraqi breast cancer women had BRAF V600E mutation, The annotated BRAF gene has been deposited in DDBJ/GenBank under the accession number LC547435. In conclusion: The present data indicate no BRAF V600E mutation in Iraqi breast cancer females and may not possess a role in breast cancer initiation. The current results may be refer to ineffectiveness of Vemurafenib and Encorafenib therapies that specific for patients with the BRAF V600 mutation. Other studies with large numbers of patients are needed to confirm the result of this study, as the high prevalence of breast cancer among Iraqi women.
},
year = {2024}
}
TY - JOUR T1 - Investigation of BRAF V600E Mutation in Breast Cancer Patients AU - Wafaa Sabri Mahood AU - Athraa Hammed Hassoon AU - Shaimaa Sabah Al Obaidy AU - Lenha Qutaiba Ahmed AU - Ibtisam Hammood AL Musawi Y1 - 2024/06/19 PY - 2024 N1 - https://doi.org/10.11648/j.abb.20241202.13 DO - 10.11648/j.abb.20241202.13 T2 - Advances in Bioscience and Bioengineering JF - Advances in Bioscience and Bioengineering JO - Advances in Bioscience and Bioengineering SP - 45 EP - 49 PB - Science Publishing Group SN - 2330-4162 UR - https://doi.org/10.11648/j.abb.20241202.13 AB - The B-Raf is the essential protein in signal pathways inside cells which is affected by cell growth direction. The B-Raf protein encoded by the BRAF gene that is located at chromosome 7, BRAF gene is also pointed out as proto-oncogene. This study aimed to detect the substitution at codon 600 causing a change of valine to glutamic acid (V600E) mutation in Iraqi females to assist its role in initiating breast cancer. Sixty biopsies tissue from breast cancer Iraqi women and 20 women with benign lesions were enrolled in this study. DNA was extracted from breast cancer biopsies samples. PCR and DNA Sequencing techniques were used to screen the BRAF V600E gene mutation as it is an essential event in the initiation of cancer. The results revealed that none Iraqi breast cancer women had BRAF V600E mutation, The annotated BRAF gene has been deposited in DDBJ/GenBank under the accession number LC547435. In conclusion: The present data indicate no BRAF V600E mutation in Iraqi breast cancer females and may not possess a role in breast cancer initiation. The current results may be refer to ineffectiveness of Vemurafenib and Encorafenib therapies that specific for patients with the BRAF V600 mutation. Other studies with large numbers of patients are needed to confirm the result of this study, as the high prevalence of breast cancer among Iraqi women. VL - 12 IS - 2 ER -
College of Education- for Pure Sciences Ibn Al-Haytham, University of Baghdad, Baghdad, Iraq
Information